Reported Saturday, UroGen Announced ATLAS Study Results At AUA 2024: UGN-102 Demonstrates Sustained Response In New And Recurrent Bladder Cancer Patients
Reported Saturday, UroGen Announced ATLAS Study Results At AUA 2024: UGN-102 Demonstrates Sustained Response In New And Recurrent Bladder Cancer Patients
- New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months
- 接受 UGN-102 治療的新患者和復發患者在 12 個月時實現了相似的耐久性緩解率 (DOR)
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier methods the probabilities of remaining in complete response for both new and recurrent low-grade intermediate-risk non- muscle invasive bladder cancer (LG-IR-NMIBC) patients following treatment with investigational drug UGN-102 as primary therapy, with or without subsequent transurethral resection of the bladder tumor (TURBT) at 3 months.
致力於開發和商業化治療尿路上皮癌和特種癌症的創新解決方案的生物技術公司UroGen Pharma Ltd.（納斯達克股票代碼：URGN）今天公佈了對ATLAS試驗的一項新分析結果，該研究使用卡普蘭·邁爾方法估算了新發和復發的低度中等風險非肌肉浸潤性膀胱癌（LG-IR-NMIBC）患者在接受研究藥物 UGN-102 治療後保持完全反應的可能性作爲主要療法，無論是否隨後的經尿道切除術3 個月時出現膀胱腫瘤 (TURBT)。